Shandong Wit Dyne HealthLtd Past Earnings Performance
Past criteria checks 3/6
Shandong Wit Dyne HealthLtd has been growing earnings at an average annual rate of 20.7%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 7.3% per year. Shandong Wit Dyne HealthLtd's return on equity is 22.6%, and it has net margins of 22.9%.
Key information
20.7%
Earnings growth rate
20.8%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | 7.3% |
| Return on equity | 22.6% |
| Net Margin | 22.9% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Is There An Opportunity With Shandong Wit Dyne Health Co.,Ltd.'s (SZSE:000915) 38% Undervaluation?
Oct 27
There's No Escaping Shandong Wit Dyne Health Co.,Ltd.'s (SZSE:000915) Muted Earnings
Sep 14Shandong Wit Dyne HealthLtd (SZSE:000915) Is Increasing Its Dividend To CN¥2.00
May 12Shandong Wit Dyne HealthLtd's (SZSE:000915) Earnings Offer More Than Meets The Eye
Apr 24Revenue & Expenses Breakdown
How Shandong Wit Dyne HealthLtd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 2,143 | 490 | 647 | 92 |
| 30 Jun 24 | 2,485 | 595 | 685 | 115 |
| 31 Mar 24 | 2,495 | 590 | 734 | 97 |
| 31 Dec 23 | 2,484 | 585 | 742 | 96 |
| 30 Sep 23 | 2,241 | 525 | 608 | 83 |
| 30 Jun 23 | 2,269 | 544 | 600 | 58 |
| 31 Mar 23 | 2,297 | 535 | 600 | 64 |
| 31 Dec 22 | 2,341 | 527 | 600 | 66 |
| 30 Sep 22 | 2,273 | 524 | 565 | 81 |
| 30 Jun 22 | 2,241 | 456 | 603 | 86 |
| 31 Mar 22 | 2,143 | 427 | 554 | 82 |
| 01 Jan 22 | 2,027 | 380 | 523 | 80 |
| 30 Sep 21 | 2,027 | 382 | 398 | 100 |
| 30 Jun 21 | 2,000 | 385 | 383 | 93 |
| 31 Mar 21 | 1,986 | 350 | 408 | 94 |
| 31 Dec 20 | 1,821 | 291 | 422 | 96 |
| 30 Sep 20 | 1,852 | 277 | 523 | 69 |
| 30 Jun 20 | 1,821 | 250 | 535 | 66 |
| 31 Mar 20 | 1,804 | 230 | 568 | 66 |
| 31 Dec 19 | 1,800 | 204 | 588 | 65 |
| 30 Sep 19 | 1,562 | 141 | 597 | 59 |
| 30 Jun 19 | 1,541 | 137 | 595 | 55 |
| 31 Mar 19 | 1,390 | 80 | 526 | 50 |
| 01 Jan 19 | 1,526 | 130 | 563 | 43 |
| 30 Sep 18 | 1,699 | 170 | 605 | 42 |
| 30 Jun 18 | 1,698 | 178 | 605 | 56 |
| 31 Mar 18 | 1,775 | 231 | 651 | 46 |
| 31 Dec 17 | 1,767 | 243 | 598 | 41 |
| 30 Sep 17 | 1,794 | 255 | 566 | 24 |
| 30 Jun 17 | 1,694 | 239 | 529 | 0 |
| 31 Mar 17 | 1,662 | 238 | 479 | 0 |
| 31 Dec 16 | 1,545 | 198 | 479 | 0 |
| 30 Sep 16 | 1,529 | 229 | 415 | 0 |
| 30 Jun 16 | 1,415 | 195 | 416 | 0 |
| 31 Mar 16 | 1,312 | 156 | 430 | 0 |
| 31 Dec 15 | 1,233 | 152 | 401 | 0 |
| 30 Sep 15 | 1,246 | 162 | 433 | 0 |
| 30 Jun 15 | 1,310 | 206 | 413 | 0 |
| 31 Mar 15 | 1,317 | 211 | 395 | 0 |
| 31 Dec 14 | 1,374 | 217 | 393 | 0 |
| 30 Sep 14 | 1,266 | 178 | 378 | 0 |
| 30 Jun 14 | 1,198 | 149 | 377 | 0 |
| 31 Mar 14 | 1,173 | 165 | 353 | 0 |
| 31 Dec 13 | 1,095 | 153 | 346 | 0 |
Quality Earnings: 000915 has high quality earnings.
Growing Profit Margin: 000915's current net profit margins (22.9%) are lower than last year (23.4%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 000915's earnings have grown significantly by 20.7% per year over the past 5 years.
Accelerating Growth: 000915's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 000915 had negative earnings growth (-6.7%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-2.5%).
Return on Equity
High ROE: 000915's Return on Equity (22.6%) is considered high.